Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.

Kathryn E BeckermannAviva G Asnis-AlibozekMichael B AtkinsBernard EscudierThomas E HutsonVijay KasturiDavid F McDermottSumanta K PalCamillo PortaBrian I RiniElena Verzoni

Published in: The oncologist (2024)

Tivozanib demonstrated a consistent safety profile and long-term survival benefit in patients with R/R advanced RCC who were alive and progression free at 12 months. These post hoc exploratory analyses of LT-PFS and conditional OS support a clinically meaningful improvement with tivozanib versus sorafenib in this advanced RCC population.

Keyphrases

phase iii
renal cell carcinoma
open label
clinical trial
phase ii
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
randomized controlled trial
hodgkin lymphoma